一种革新心脏瓣膜病治疗的新技术体系:经导管主动脉瓣治疗主动脉瓣狭窄
A new technological system to revolutionize the management of valvular heart diseases: transcatheter aortic valve for the treatment of aortic stenosis
摘要:
本研究的目的是对基于经导管人工主动脉瓣、输送导管和装载系统的治疗主动脉瓣狭窄的新技术体系给心脏瓣膜病治疗带来的一场革命进行技术分析(由于钙积聚限制了流向主动脉的血流而导致主动脉瓣变窄,身体的主要动脉)在中等和更高风险的患者中进行手术治疗。特别是,本研究分析了经导管主动脉瓣植入术(TAVI)新技术与外科主动脉瓣置换术(SAVR)既定技术的技术轨迹。为了探索心脏瓣膜疾病的新兴技术TAVI,应用模型来显示新的TAVI技术如何取代SAVR的成熟技术,以彻底改变心脏病学中主动脉瓣狭窄的治疗。统计分析显示,TAVI的科学生产急剧增加,其增长系数作为时间的函数等于0.40(p<.001),而SAVR技术的增长系数为0.10(p<.001)。这一发现表明了一个技术预测,即TAVI将成为治疗心脏瓣膜病患者的主导技术。总的来说,这项研究表明,2002年引入的经导管主动脉瓣植入术(TAVI)新技术在科学、发明和创新活动方面正在发展,以彻底改变全球心脏病学中主动脉瓣狭窄的管理。
英文摘要:
The goal of this study is a technology analysis of a revolution for the management of valvular heart diseases given by new technological system based on transcatheter artificial aortic valve, a delivery catheter and a loading system for the treatment of aortic stenosis (a narrowing of the aortic valve because of calcium build up that restricts blood flow to aorta, the body's main artery) in patients at intermediate and greater risk for surgical therapy. In particular, this study analyzes the technological trajectories of new technology of transcatheter aortic valve implantation (TAVI) in relation to the established technology of surgical aortic valve replacement (SAVR). To explore the emerging technology of TAVI for valvular heart diseases, a model is applied to show how new TAVI technology is substituting established technologies of SAVR to revolutionize the management of aortic stenosis in cardiology. Statistical analyses reveal the sharp increase of the scientific production of TAVI that has a coefficient of growth as function of time equal to 0.40 (p<.001) versus a coefficient for SAVR technology of 0.10 (p<.001). This finding suggests a technological forecasting that TAVI will be the dominant technology for the treatment of patients with valvular heart diseases. Overall, then, this study shows that new technology of transcatheter aortic valve implantation (TAVI) introduced in 2002 is growing in terms of scientific, inventive and innovative activity to revolutionize the management of aortic stenosis in cardiology worldwide.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。